Who is sponsoring NCT06235853?

NCT06235853 is sponsored by Wroclaw Medical University.

What drugs are being tested in NCT06235853?

Interventions in NCT06235853: Blood serum: sUPAR, PAI-1, IL-8., Urine: IL-8, APOE, VEGF..

What condition does NCT06235853 study?

NCT06235853 studies Non-muscle Invasive Bladder Cancer, Cystoscopy, Recurrence, Progression, Bladder Cancer, Biomarkers.

Is NCT06235853 still recruiting?

NCT06235853 is currently completed. Last updated 1 February 2024.

Last reviewed 2024-02-01 · How we verify

NCT06235853

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer

Completed Last updated 1 February 2024

What this trial tests

trial testing Blood serum: sUPAR, PAI-1, IL-8. in Non-muscle Invasive Bladder Cancer in 240 participants. Completed in 30 April 2023.

Timeline

1 January 2020

Primary endpoint
31 December 2022

30 April 2023

Quick facts

Lead sponsor	Wroclaw Medical University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	240
Start date	1 January 2020
Primary completion	31 December 2022
Estimated completion	30 April 2023
Sites	1 location across Poland

Drugs / interventions tested

Blood serum: sUPAR, PAI-1, IL-8.
Urine: IL-8, APOE, VEGF.

Conditions studied

Non-muscle Invasive Bladder Cancer — all drugs for Non-muscle Invasive Bladder Cancer →
Cystoscopy — all drugs for Cystoscopy →
Recurrence — all drugs for Recurrence →
Progression — all drugs for Progression →

Sponsor

Wroclaw Medical University

Who can join

18 and older, any sex, with Non-muscle Invasive Bladder Cancer or Cystoscopy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bladder cancer (BC) is one of the most common type of cancer globally. Due to its high incidence rate, high risk of recurrence and progression, and frequent cystoscopy surveillance, BC contributes to major healthcare costs across the world. The goal of this prospective study was to evaluate the prognostic value of novel non-muscle invasive bladder cancer (NMIBC) biomarkers for predicting disease recurrence or progression after radical transurethral resection of bladder tumour (TURBT). The data obtained from this study may help physicians identify patients who are at greater risk of NMIBC recurrence or progression and require close supervision.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Evaluation of six novel biomarkers for predicting recurrence of non-muscle invasive bladder cancer after endoscopic resection- a prospective observational study.
Bardowska K, Krajewski W, Kołodziej A, Kościelska-Kasprzak K, et al · · 2025 · cited 2× · PMID 39928162 · DOI 10.1007/s00345-025-05485-9
Preoperative systemic inflammatory biomarkers can improve recurrence prediction of non-muscle invasive bladder cancer after endoscopic resection - a prospective observational study.
Bardowska K, Krajewski W, Kołodziej A, Kościelska-Kasprzak K, et al · · 2025 · PMID 40620890 · DOI 10.5114/wo.2025.151064

Verify or expand the search:

Other recruiting trials for Non-muscle Invasive Bladder Cancer

Currently open trials in the same condition.

NCT07206225 — A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer · Phase 1 · recruiting
NCT06503614 — A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT06632964 — A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder C · Phase 1 · recruiting
NCT07252297 — The Role of Universal Cancer Only Marker SIX6 in Diagnosing Non-Muscle Invasive Bladder Cancer · NA · active not recruiting
NCT04165317 — A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer · Phase 3 · active not recruiting

Other Wroclaw Medical University trials

Trials by the same sponsor.

NCT07413419 — Evaluation of Remote Motivational Interviewing for Disease Management in Heart Failure Patients and Their Carers · NA · not yet recruiting
NCT07159932 — Poland Integrated Medicines Management (PL-IMM) - Study Assessing the Provision of Complex Clinical Pharmacy Services to · NA · not yet recruiting
NCT07141745 — Electroporation vs. Radiofrequency Ablation Guided by 3D Imaging in Repeat Procedures for Atrial Fibrillation · NA · recruiting
NCT07099885 — Simple Urine Composition-based Personalized Algorithm for Effective Congestion Relief in Decompensated Heart Failure · NA · recruiting
NCT07157475 — Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06235853 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wroclaw Medical University
Last refreshed: 1 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06235853.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing